x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230017
| Product Information | |
|---|---|
| CAS No. | 475110-96-4 |
| Chemical Name | 4-[4-[2-(Difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine |
| Formula | C19H21F2N7O2 |
| Molecular Weight | 417.41 |
| PubChem CID | 11647372 |
| SMILES | C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5 |
| Target | Other |
| Product Description | Potent, ATP-competitve PI3K inhibitor |
| Format & Storage | |
|---|---|
| Purity | > 99% |
| Source | Synthetic |
| Shipping | Shipped on dry ice. |
| Storage | Store at -20 °C. Store under desiccating conditions. The product can be stored for up to 12 months. |
| Solubility Overview | Soluble in DMSO to 50 mM |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
